The estimated Net Worth of Marella Thorell is at least $5.55 ezer dollars as of 7 November 2023. Marella Thorell owns over 6,500 units of Evelo Biosciences Inc stock worth over $542 and over the last 4 years Marella sold EVLO stock worth over $5,009.
Marella has made over 5 trades of the Evelo Biosciences Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Marella exercised 6,500 units of EVLO stock worth $146 on 7 November 2023.
The largest trade Marella's ever made was exercising 130,000 units of Evelo Biosciences Inc stock on 7 May 2023 worth over $2,925. On average, Marella trades about 16,169 units every 15 days since 2020. As of 7 November 2023 Marella still owns at least 24,070 units of Evelo Biosciences Inc stock.
You can see the complete history of Marella Thorell stock trades at the bottom of the page.
Marella's mailing address filed with the SEC is C/O ESSA PHARMA INC., 999 WEST BROADWAY, SUITE 720, VANCOUVER, A1, V5Z 1K5.
Over the last 7 years, insiders at Evelo Biosciences Inc have traded over $41,656 worth of Evelo Biosciences Inc stock and bought 38,579,214 units worth $81,620,674 . The most active insiders traders include Ventures Fund Iv General Pa..., Noubar Afeyan és Ventures Fund Iv General Pa.... On average, Evelo Biosciences Inc executives and independent directors trade stock every 45 days with the average trade being worth of $19,676. The most recent stock trade was executed by Mark Bodmer on 7 November 2023, trading 6,625 units of EVLO stock currently worth $149.
evelo biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. these new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. by finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, evelo can improve the speed, cost and success of drug discovery and development. evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. evelo biosciences was conceived and created within venturelabs®, flag
Evelo Biosciences Inc executives and other stock owners filed with the SEC include: